LOS ANGELES–(BUSINESS WIRE)–Catasys, Inc. (NASDAQ:CATS) (“Catasys” or the “Company”), a leading AI and technology-enabled healthcare company, today announced that the Company will be releasing financial results for its fourth quarter and year ended December 31, 2018, after the closing of the stock market on Thursday, March 14, 2019. The Company will […]
Other News
Itamar Medical to Present at the Oppenheimer 29th Annual Healthcare Conference on March 20, 2019
CAESAREA, Israel, March 12, 2019 (GLOBE NEWSWIRE) — Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), a medical device company that develops, manufactures and markets non-invasive diagnostic medical devices for sleep apnea with a focus on the cardiology market, announced today that Gilad Glick, Chief Executive Officer of Itamar Medical, will […]
Stereotaxis Reports 2018 Full Year Financial Results
ST. LOUIS, March 12, 2019 (GLOBE NEWSWIRE) — Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the fourth quarter and full year ended December 31, 2018. “2018 was an extremely active year at Stereotaxis with progress […]
Micro Medical Solutions Signs Distribution Agreements in 15 Countries for MicroStent Vascular Stent
WILMINGTON, Mass., March 12, 2019 /PRNewswire/ — Micro Medical Solutions (MMS), an innovator in the field of microvascular interventions that improve clinical outcomes and quality of life, announced today that it has established distribution agreements for MicroStent in 15 countries in the European Union and Latin America. MicroStent is a vascular stent specifically […]
Neovasc Announces Agreements to Exchange Outstanding Warrants for Shares
VANCOUVER, March 12, 2019 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN) (TSX: NVCN) announced today that it has entered into exchange agreements (“Exchange Agreements”) with the holders (“Holders”) of all of its outstanding Series A common share purchase warrants and Series E common share purchase warrants (collectively, the “Warrants”) issued pursuant […]
Zynex Expands Corporate Headquarters to Accommodate Growth
ENGLEWOOD, Colo., March 12, 2019 /PRNewswire/ — Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, announced today that it has signed an addendum to its corporate headquarters building lease expanding the footprint to 63,000 square feet, […]
William T. Abraham, MD, joins V-Wave as Chief Medical Officer
CAESAREA, Israel, March 12, 2019 /PRNewswire/ — V-Wave Ltd., an early stage medtech company developing an implantable interatrial shunt device for treating advanced heart failure (HF) and pulmonary arterial hypertension (PAH), announced today that renowned heart failure cardiologist, William T. Abraham, MD, is joining V-Wave as Chief Medical Officer. Dr. Abraham makes this move […]
AstraZeneca to Present New Cardiovascular Data on FARXIGA in Type 2 Diabetes At ACC 2019
WILMINGTON, Del.–(BUSINESS WIRE)–Data evaluating the cardiovascular (CV) effects of FARXIGA® (dapagliflozin),including hospitalization for heart failure (hHF) in adults with type 2 diabetes (T2D) have been selected for late-breaking clinical trial and oral presentations at the American College of Cardiology’s (ACC) 68th Annual Scientific Session on March 16-18. The data are the […]
Caladrius Biosciences to Present at the Alliance for Regenerative Medicine 7th Annual Cell & Gene Therapy Investor Day
BASKING RIDGE, N.J., March 11, 2019 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company committed to the development of innovative products that have the potential to restore the health of people with chronic illnesses and with a focus on select […]
Espero BioPharma Announces Tecarfarin Receives FDA Orphan Drug Designation for Patients with End Stage Renal Disease and Atrial Fibrillation
JACKSONVILLE, Fla. and IRVINE, Calif., March 11, 2019 (GLOBE NEWSWIRE) — Espero BioPharma, Inc., a pharmaceutical company focused on the development of therapeutics for unmet needs in thrombosis and cardiac rhythm control, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for tecarfarin […]



